Please login to the form below

Not currently logged in
Email:
Password:

aflibercep

This page shows the latest aflibercep news and features for those working in and with pharma, biotech and healthcare.

NICE first fast-track appraisal backs Bayer's Eylea

NICE first fast-track appraisal backs Bayer's Eylea

The National Institute for Health and Care Excellence (NICE) has issued its first fast-track guidance, recommending Bayer’s Eylea (aflibercep) in choroidal neovascularisation (CNV).

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics